



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,423)

GAU 1614
#4 B.H.

In the Application of:

Jeff A. Zablocki, et al.

Examiner: Not Assigned

Serial No.: 09/338,185

Group Art Unit: 1614

Filed: June 22, 1999

Title: N-Pyrazole A_{2A} Receptor Agonists

Asst. Commissioner for Patents
Washington, D.C. 20231

RECEIVED

MAY 12 2000

Sir:

TECH CENTER 1600/2900

TRANSMITTAL LETTER

In regard to the above identified application:

1. We are transmitting herewith the attached:
 - a. Information Disclosure Statement citing 16 references
 - b. Form PTO-1449
2. With respect to additional fees:
 - a. _____ Attached is a check in the amount of \$-0-
3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
4. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Asst. Commissioner for Patents, Washington, D.C. 20231 on this 24th day of May, 2000.

By

C. BL Hughes
A Blair Hughes
Reg. No. 32,901

McDONNELL BOEHNNEN HULBERT
& BERGHOFF
300 South Wacker Drive, 32nd Floor
Chicago, Illinois 60606



#4

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 99,423)

In the Application of:

Jeff A. Zablocki, et al.

Serial No. 09/338,185

Filed: June 22, 1999

Title: N-Pyrazole A_{2A} Receptor
Agonists

Examiner:

Group Art Unit: 1614

RECEIVED
MAY 12 2000
TECH CENTER 1600/2800INFORMATION DISCLOSURE STATEMENTAsst. Commissioner of Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97-1.98, applicants wish to make the following references of record in the above-identified application. These references may be material to the Examiner's consideration of the presently pending claims. Copies of the references cited below are enclosed along with a completed Form-1449.

U.S. Patents

	<u>Patent Number</u>	<u>Inventor</u>	<u>Issue Date</u>
1.	5,593,975	Cristalli	January 14, 1997
2.	5,189,027	Miyashita et al.	February 23, 1993

McDONNELL BOEHNEN HULBERT & BERGHOFF
300 South Wacker Drive, 32nd Floor
Chicago, Illinois 60606

	<u>Patent No.</u>	<u>Inventors</u>	<u>Issue Date</u>
3.	4,956,345	Miyasaka et al.	September 11, 1990
4.	5,270,304	Kogi et al.	December 14, 1993
5.	5,459,254	Yamaguchi et al.	October 17, 1995
6.	5,705,491	Yamada	January 6, 1998
7.	5,770,716	Khan et al.	June 23, 1998
8.	5,939,543	Morozumi et al.	August 17, 1999

Foreign Patents

	<u>Application Number</u>	<u>Publication Date</u>
1.	965,411 (Canada)	April 1, 1975
2.	Hei 5[1993]-9197 (Japan)	January 19, 1993

Printed Publications

1. Marumoto, et al., "Synthesis and Coronary Vaso-dilating Activity of 2-Substituted Adenosines", *Chem. Pharm. Bull.* 23(4): 759-774 (1975).
2. Marumoto, et al., "Synthesis and Enzymatic Activity of Adenosine 3',5'-Cyclic Phosphate Analogs", *Chem. Pharm. Bull.* 27(4) 990-1003 (1979).
3. Persson, et al., "Synthesis and Antiviral Effects of 2-Heteroaryl Substituted Adenosine and 8-Heteroaryl Substituted Guanosine Derivatives", *Bioorganic & Medicinal Chemistry*, 3:1377-1382 (1995).
4. Mager, et al., "Molecular simulation applied to 2-(N'-alkylidenehydrazino)- and 2-(N'-aralkylidenehydrazino) adenosine A₂ Agonists", *Eur J. Med. Chem.* 30:15-25 (1995).


5. Cristalli et al., "2-Alkynyl Derivatives of Adenosine 5'-N'ethyluronamide: Selective A₂ Adenosine Receptor Agonists with Potent Inhibitory Activity on Platelet Aggregation", *J. Med. Chem.*, 37:1720-1726 (1994).
6. Matsuda, et al., "Nucleosides and Nucleotides. 103. 2-Alkynyladenosines: A Novel Class of Selective Adenosine A₂ Receptor Agonists with Potent Antihypertensive Effects", *J. Med. Chem.* 35:241-252 (1992).

Respectfully submitted,

McDONNELL BOEHNEN HULBERT &
BERGHOFF

Dated: May 4, 2000

By:


A. Blair Hughes
Reg. No. 32,901